^
    Back
    Association details:
    Biomarker:XPC K939G
    Cancer:Osteosarcoma
    Drug:cisplatin (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    Nature
    Title:

    Common variations in ERCC2 are associated with response to cisplatin chemotherapy and clinical outcome in osteosarcoma patients

    Excerpt:
    Eight single nucleotide polymorphisms in ERCC2, XPC, XPA, ERCC1, ERCC4 and ERCC5 genes were analyzed in 91 patients diagnosed with osteosarcoma and treated with cisplatin….On the contrary, the polymorphic C allele of XPC Lys939Gln was significantly associated with good response (OR=0.34, 95% CI=0.12–0.91, P-value=0.032).
    DOI:
    10.1038/tpj.2009.19